When I last mentioned ATRI it closed at approximately $171 a share. Since then, in addition to paying regular quarterly dividends of $0.42/share, the company also paid a $3 special dividend, while the stock price last week rose to more than $200.
Until early May, ATRI shares made no progress whatsoever. However, a blow-out 11Q1 earnings report (up more than 40% YoY) on record revenue and commentary from management has led to a strong rally over the past 7 weeks with the stock hitting $200 in late June.
ATRI remains a relatively undiscovered gem. With a market cap now nearly $400 million, ATRI may start to hit a few more radar screens.
The chart indicates that there should be support in the 185 area, and it looks as if 2011 eps could come in at more than $12/share compared to my December post estimate of $11.50-$11.75.
The stock seems always to be a buy when it has a pullback.
Saturday, July 2, 2011
Mid-Year Review: Progress Continues at SPA
On the day of my last post about SPA, the stock has risen from $8.06 to the July 1 close of $10.09.
That's a gain of about 25%.
The company continues to maintain a substantial cash balance (over $2.50 a share) and still is debt-free.
For the fiscal year ended June 30, 2011, it appears that SPA may come in with e.p.s. in the range of $0.80-$0.90 per share.
With two modest acquisitions completed in the past FY (one for about $10 million and one for about $4 million), another acquisition seems like the next possible catalyst aside from a good June-quarter earnings report.
I've cut back my position size a bit here but this remains my biggest position.
That's a gain of about 25%.
The company continues to maintain a substantial cash balance (over $2.50 a share) and still is debt-free.
For the fiscal year ended June 30, 2011, it appears that SPA may come in with e.p.s. in the range of $0.80-$0.90 per share.
With two modest acquisitions completed in the past FY (one for about $10 million and one for about $4 million), another acquisition seems like the next possible catalyst aside from a good June-quarter earnings report.
I've cut back my position size a bit here but this remains my biggest position.
Mid-Year Review: ALIM/PSDV is Not Working
The ALIM drug for the treatment of diabetic macular edema did not recieve an approval from the FDA and both stocks have suffered since that event in December. Still, the stock's have more or less gone sideways over the past few months.
The drug (actually, a drug-delivering device) will again be evaluated by the FDA in mid-November 2011. Things are on hold until then, but ALIM appears to need to raise a bit of additional capital to get a launch underway if it is approved.
This one is only for highly risk-tolerant speculators, as is typical of development-stage drug outfits.
This one has been a bummer!
The drug (actually, a drug-delivering device) will again be evaluated by the FDA in mid-November 2011. Things are on hold until then, but ALIM appears to need to raise a bit of additional capital to get a launch underway if it is approved.
This one is only for highly risk-tolerant speculators, as is typical of development-stage drug outfits.
This one has been a bummer!
Mid-year Review: PLNR
Planar -- PLNR -- $2.88
PLNR is up from $2.10 at the time of my 18 November 2010 recommendation to $2.88, a gain of more than 35%. Not bad for a bit over 6 months. Since the recommendation, management has identified the "Quick Serve Restaurant" industry as a significant driver of revenue growth over the intermediate term. They have indicated that management has significantly improved visibility into future growth for displays that will allow companies such as McDonald's to upgrade the displays used in their drive-through lanes.
Indeed, the movement in the stock's price coincided with an analyst trip that MCD sponsored for Wall Street analysts to visit two of their "model" new "remodels".
If the 11Q2 earnings report soon to be reported does not demonstrate continued improvement in financial performance, the stock could pull back, but the intermediate-term outlook appears to favor higher prices in another 6 months as long as the world doesn't completely fall apart, thanks in part to the company's still-significant cash position and debt free status.
PLNR is up from $2.10 at the time of my 18 November 2010 recommendation to $2.88, a gain of more than 35%. Not bad for a bit over 6 months. Since the recommendation, management has identified the "Quick Serve Restaurant" industry as a significant driver of revenue growth over the intermediate term. They have indicated that management has significantly improved visibility into future growth for displays that will allow companies such as McDonald's to upgrade the displays used in their drive-through lanes.
Indeed, the movement in the stock's price coincided with an analyst trip that MCD sponsored for Wall Street analysts to visit two of their "model" new "remodels".
If the 11Q2 earnings report soon to be reported does not demonstrate continued improvement in financial performance, the stock could pull back, but the intermediate-term outlook appears to favor higher prices in another 6 months as long as the world doesn't completely fall apart, thanks in part to the company's still-significant cash position and debt free status.
Subscribe to:
Comments (Atom)